Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib.

Kok CH, Yeung DT, Lu L, Watkins DB, Leclercq TM, Dang P, Saunders VA, Reynolds J, White DL, Hughes TP.

Blood Adv. 2019 May 28;3(10):1610-1621. doi: 10.1182/bloodadvances.2019000195.

2.

Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia.

Ross DM, Pagani IS, Irani YD, Clarson J, Leclercq T, Dang P, McLean J, Saunders VA, Carne L, Reynolds J, Ritchie DS, White DL, Branford S, Hughes TP, Yong ASM.

Br J Haematol. 2019 Aug;186(3):e56-e60. doi: 10.1111/bjh.15894. Epub 2019 Mar 27. No abstract available.

PMID:
30916385
3.

Modelling ponatinib resistance in tyrosine kinase inhibitor-naïve and dasatinib resistant BCR-ABL1+ cell lines.

Lu L, Kok CH, Saunders VA, Wang J, McLean JA, Hughes TP, White DL.

Oncotarget. 2018 Oct 5;9(78):34735-34747. doi: 10.18632/oncotarget.26187. eCollection 2018 Oct 5.

4.

Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells.

Ross DM, Pagani IS, Shanmuganathan N, Kok CH, Seymour JF, Mills AK, Filshie RJ, Arthur CK, Dang P, Saunders VA, Braley J, Yong AS, Yeung DT, White DL, Grigg AP, Schwarer AP, Branford S, Hughes TP; Australasian Leukaemia and Lymphoma Group (ALLG).

Leukemia. 2018 Dec;32(12):2572-2579. doi: 10.1038/s41375-018-0264-0. Epub 2018 Oct 12.

PMID:
30315232
5.

BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia.

Pagani IS, Dang P, Kommers IO, Goyne JM, Nicola M, Saunders VA, Braley J, White DL, Yeung DT, Branford S, Hughes TP, Ross DM.

Haematologica. 2018 Dec;103(12):2026-2032. doi: 10.3324/haematol.2018.189787. Epub 2018 Jul 5.

6.

The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro.

Eadie LN, Saunders VA, Branford S, White DL, Hughes TP.

Oncotarget. 2018 Feb 3;9(17):13423-13437. doi: 10.18632/oncotarget.24393. eCollection 2018 Mar 2.

7.

A Method for Next-Generation Sequencing of Paired Diagnostic and Remission Samples to Detect Mitochondrial DNA Mutations Associated with Leukemia.

Pagani IS, Kok CH, Saunders VA, Van der Hoek MB, Heatley SL, Schwarer AP, Hahn CN, Hughes TP, White DL, Ross DM.

J Mol Diagn. 2017 Sep;19(5):711-721. doi: 10.1016/j.jmoldx.2017.05.009. Epub 2017 Jul 18.

PMID:
28732215
8.

Increased peroxisome proliferator-activated receptor γ activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells.

Wang J, Lu L, Kok CH, Saunders VA, Goyne JM, Dang P, Leclercq TM, Hughes TP, White DL.

Haematologica. 2017 May;102(5):843-853. doi: 10.3324/haematol.2016.153270. Epub 2017 Feb 2.

9.

The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment.

Eadie LN, Dang P, Saunders VA, Yeung DT, Osborn MP, Grigg AP, Hughes TP, White DL.

Leukemia. 2017 Jan;31(1):75-82. doi: 10.1038/leu.2016.179. Epub 2016 Jun 24.

PMID:
27416909
10.

Ponatinib is not transported by ABCB1, ABCG2 or OCT-1 in CML cells.

Lu L, Saunders VA, Leclercq TM, Hughes TP, White DL.

Leukemia. 2015 Aug;29(8):1792-4. doi: 10.1038/leu.2015.35. Epub 2015 Feb 13. No abstract available.

PMID:
25676419
11.

Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells.

White DL, Eadie LN, Saunders VA, Hiwase DK, Hughes TP.

Leukemia. 2013 Apr;27(5):1201-4. doi: 10.1038/leu.2012.295. Epub 2012 Oct 16. No abstract available.

PMID:
23164803
12.

Dasatinib targets chronic myeloid leukemia-CD34+ progenitors as effectively as it targets mature cells.

Hiwase DK, Saunders VA, Nievergall E, Ross DD, White DL, Hughes TP.

Haematologica. 2013 Jun;98(6):896-900. doi: 10.3324/haematol.2012.070268. Epub 2012 Oct 12.

13.

Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2.

Eadie LN, Saunders VA, Hughes TP, White DL.

Leuk Lymphoma. 2013 Mar;54(3):569-78. doi: 10.3109/10428194.2012.715345. Epub 2012 Aug 21.

PMID:
22845311
14.

Contrasting effects of diclofenac and ibuprofen on active imatinib uptake into leukaemic cells.

Wang J, Hughes TP, Kok CH, Saunders VA, Frede A, Groot-Obbink K, Osborn M, Somogyi AA, D'Andrea RJ, White DL.

Br J Cancer. 2012 May 22;106(11):1772-8. doi: 10.1038/bjc.2012.173. Epub 2012 Apr 24.

15.

Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib.

White DL, Radich J, Soverini S, Saunders VA, Frede AK, Dang P, Cilloni D, Lin P, Mongay L, Woodman R, Manley P, Slader C, Kim DW, Pane F, Martinelli G, Saglio G, Hughes TP.

Haematologica. 2012 Jun;97(6):907-14. doi: 10.3324/haematol.2011.056457. Epub 2011 Dec 29.

16.

OCT-1 activity measurement provides a superior imatinib response predictor than screening for single-nucleotide polymorphisms of OCT-1.

White DL, Saunders VA, Dang P, Engler J, Hughes TP.

Leukemia. 2010 Nov;24(11):1962-5. doi: 10.1038/leu.2010.188. Epub 2010 Sep 2. No abstract available.

PMID:
20811406
17.

Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib.

White DL, Dang P, Engler J, Frede A, Zrim S, Osborn M, Saunders VA, Manley PW, Hughes TP.

J Clin Oncol. 2010 Jun 1;28(16):2761-7. doi: 10.1200/JCO.2009.26.5819. Epub 2010 Apr 26.

PMID:
20421539
18.

Rule-based simulation of temperate bacteriophage infection: restriction-modification as a limiter to infection in bacterial populations.

Gregory R, Saunders VA, Saunders JR.

Biosystems. 2010 Jun;100(3):166-77. doi: 10.1016/j.biosystems.2010.02.010. Epub 2010 Mar 6.

PMID:
20211223
19.

Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity.

Engler JR, Frede A, Saunders VA, Zannettino AC, Hughes TP, White DL.

Leukemia. 2010 Apr;24(4):765-70. doi: 10.1038/leu.2010.16. Epub 2010 Feb 11.

PMID:
20147974
20.

Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors.

Hiwase DK, White DL, Powell JA, Saunders VA, Zrim SA, Frede AK, Guthridge MA, Lopez AF, D'Andrea RJ, To LB, Melo JV, Kumar S, Hughes TP.

Leukemia. 2010 Apr;24(4):771-8. doi: 10.1038/leu.2009.299. Epub 2010 Feb 4.

PMID:
20130598
21.

Short-term intense Bcr-Abl kinase inhibition with nilotinib is adequate to trigger cell death in BCR-ABL(+) cells.

Hiwase DK, White DL, Saunders VA, Kumar S, Melo JV, Hughes TP.

Leukemia. 2009 Jun;23(6):1205-6. doi: 10.1038/leu.2009.45. Epub 2009 Mar 5. No abstract available.

PMID:
19262594
22.

Rule-based computing system for microbial interactions and communications: evolution in virtual bacterial populations.

Gregory R, Saunders VA, Saunders JR.

Biosystems. 2008 Jan;91(1):216-30. Epub 2007 Oct 2.

PMID:
18023963
23.

Rule-based modelling of conjugative plasmid transfer and incompatibility.

Gregory R, Saunders JR, Saunders VA.

Biosystems. 2008 Jan;91(1):201-15. Epub 2007 Oct 2.

PMID:
18023962
24.

Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity.

White DL, Saunders VA, Dang P, Engler J, Venables A, Zrim S, Zannettino A, Lynch K, Manley PW, Hughes T.

Blood. 2007 Dec 1;110(12):4064-72. Epub 2007 Aug 30.

PMID:
17761829
25.

Imatinib increases the intracellular concentration of nilotinib, which may explain the observed synergy between these drugs.

White DL, Saunders VA, Quinn SR, Manley PW, Hughes TP.

Blood. 2007 Apr 15;109(8):3609-10. No abstract available.

PMID:
17409347
26.

Assessing the potential of bacterial DNA profiling for forensic soil comparisons.

Heath LE, Saunders VA.

J Forensic Sci. 2006 Sep;51(5):1062-8.

PMID:
17018082
27.

The Paton individual-based model legacy.

Gregory R, Saunders JR, Saunders VA.

Biosystems. 2006 Jul;85(1):46-54. Epub 2006 Apr 4.

PMID:
16600474
28.

OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib.

White DL, Saunders VA, Dang P, Engler J, Zannettino AC, Cambareri AC, Quinn SR, Manley PW, Hughes TP.

Blood. 2006 Jul 15;108(2):697-704. Epub 2006 Apr 4.

PMID:
16597591
30.

Microdissection and chromosome painting of plant B chromosomes.

Houen A, Field BL, Saunders VA.

Methods Cell Sci. 2001;23(1-3):115-24.

PMID:
11741148
31.

Potential chitinase activating factor from yeast cells of Candida albicans.

Jackson DJ, Saunders VA, Humphreys AM.

Lett Appl Microbiol. 1996 Sep;23(3):159-62.

PMID:
8862020
32.

Monoclonal antibodies for Streptomyces lividans and their use for immunomagnetic capture of spores from soil.

Wipat A, Wellington MH, Saunders VA.

Microbiology. 1994 Aug;140 ( Pt 8):2067-76.

PMID:
7522847
33.

Streptomyces marker plasmids for monitoring survival and spread of streptomycetes in soil.

Wipat A, Wellington EM, Saunders VA.

Appl Environ Microbiol. 1991 Nov;57(11):3322-30.

34.

Growth and survival of streptomycete inoculants and extent of plasmid transfer in sterile and nonsterile soil.

Wellington EM, Cresswell N, Saunders VA.

Appl Environ Microbiol. 1990 May;56(5):1413-9.

35.
36.
37.
39.

Accumulation of gentamicin by Staphylococcus aureus: the role of the transmembrane electrical potential.

Gilman S, Saunders VA.

J Antimicrob Chemother. 1986 Jan;17(1):37-44.

PMID:
3949638
40.

Channels in membranes.

Saunders VA.

Nature. 1978 Nov 9;276(5684):116-7. No abstract available.

PMID:
368643
41.

Genetics of Rhodospirillaceae.

Saunders VA.

Microbiol Rev. 1978 Jun;42(2):357-84. Review. No abstract available.

42.
43.

Detection of two further beta-type cytochromes in Rhodopseudomonas spheroides.

Saunders VA, Jones OT.

Biochim Biophys Acta. 1975 Aug 11;396(2):220-8.

PMID:
1080425
44.

Adaptation in Rhodopseudomonas spheroides.

Saunders VA, Jones OT.

FEBS Lett. 1974 Aug 25;44(2):169-72. No abstract available.

45.

Properties of the cytochrome a-like material developed in the photosynthetic bacterium Rhodopseudomonas spheroides when grown aerobically.

Saunders VA, Jones OT.

Biochim Biophys Acta. 1974 Mar 26;333(3):439-45. No abstract available.

PMID:
4367961
46.

Oxidative phosphorylation and effects of aerobic conditions on Rhodopseudomonas viridis.

Saunders VA, Jones OT.

Biochim Biophys Acta. 1973 Jun 28;305(3):581-9. No abstract available.

PMID:
4354792
47.

Kinetic and thermodynamic properties of membrane-bound cytochromes of aerobically and photosynthetically grown Rhodopseudomonas spheroides.

Connelly JL, Jones OT, Saunders VA, Yates DW.

Biochim Biophys Acta. 1973 Apr 5;292(3):644-53. No abstract available.

PMID:
4540949
48.

Energy-linked electron transfer reactions in Rhodopseudomonas viridis.

Jones OT, Saunders VA.

Biochim Biophys Acta. 1972 Sep 20;275(3):427-36. No abstract available.

PMID:
4403603

Supplemental Content

Loading ...
Support Center